Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | BRS3 | P32247 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1085496 | 0.80 | NOX1 (0.40) | BRS3 | |
| SCHEMBL1085261 | 0.80 | BRS3 (0.39) | BRS3PNMT | |
| SCHEMBL1085529 | 0.70 | BRS3 (0.44) | BRS3 | |
| SCHEMBL17803332 | 0.68 | MEN1 (0.33) | BRS3 | |
| SCHEMBL1085374 | 0.68 | BRS3 (0.35) | BRS3 | |
| SCHEMBL1085560 | 0.64 | BRS3 (0.39) | BRS3ADRA2APNMT | |
| SCHEMBL12066730 | 0.64 | CYP11B1 (0.38) | — | |
| SCHEMBL16563723 | 0.61 | XIAP (0.47) | — | |
| SCHEMBL21760178 | 0.60 | KDM4E (0.48) | TDP2TGM2CES1ADRA2APNMT | |
| SCHEMBL21377068 | 0.60 | TGM2 (0.38) | TDP2TGM2CES1ADRA2APNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153626-B2 | Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100317645-A1 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS | MERCK SHARP & DOHME LLC | 2010-12-16 | — | — | US | disclosed |
| EP-2102201-B1 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK SHARP & DOHME (US) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317645-A1 | SUBSTITUTED DIAZEPINE SULFONAMIDES AS BOMBESIN RECEPTOR SUBTYPE-1 MODULATORS | BRS3, BRSK1, BRSK2 | TDP2 4122/4885BRS3 1/4885TGM2 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.